Sept. 20, 2010 9:00 PM
OTCMB Alert: .007
Closed: .0102 +45.71%
Dear Subscribers,
Hopefully you got in on our featured stock PLBI today. It closed up +45.7% on
massive volume.
With a strong closing and unusually high volume, this could just be the
beginning of an even bigger rally. If you haven't already read the news, make
sure to do so (see below).
To better understand the significance of why investors are warming to PLBI and
wanting to become a part of it by investing, investors should carefully review
the website of its wholly owned subsidiary RegenoBody:
Stem Cell Therapy | Regenobody Stem Cells Treatment Clinic | Dominican Republic Stem Cells Clinic
PLBI is at the forefront of the most amazing medical breakthroughs to surface in
modern times.
From their website:
Adult Stem Cell Therapy is safe, highly effective and presents minimal risk. It
begins with a complete medical evaluation performed by the patient's personal
doctor, who will use the necessary documentation sent by us, to determine the
patient's overall health and eligibility for therapy.
Once qualified, Adult Stem Cells are extracted from the patient's own blood
and/or fat, via a standard draw procedure. Since it is the patient's own cells,
there is no possibility of the body rejecting its own stem cells. This makes the
procedure very safe and non-controversial. The few naturally occurring stem
cells are then cultivated into millions of RegenoCells.
The RegenoCell are then sent to their Clinics in Sosua and re-injected back
into the patient's via a IV or IM injection. There they stimulate tissue
re-growth and greater blood flow to the affected areas. Because RegenoCells are
extracted from the patient's own body they cannot be rejected by the patient's
body.
A full report is prepared by the treating physician. Follow-up exams will be
handled in the Dominican Republic at our RegenoBody Clinical Center, and all
medical information is provided to your personal physician.
Proton Laboratories Inc., (PLBI.PK), through Regenobody S.A. ("Regenobody"), a
Dominican Republic ("DR") company has been licensed by the DR government to
investigate, experiment, treat and develop autologus stem cells for regenerating
one's own cellular tissues. Regenobody has the exclusive rights in its territory
to the RNL BIO Company Ltd. of Korean systems and equipment for the banking,
manufacture and right to purchase stem cells from RNL-BIO for a period of 20
years. The license extends to all of the Caribean, Central and South America.
RNL-BIO Company Ltd.
? LATEST NEWS ?
Proton Laboratories, Inc./RegenoBody Announces Delivery of Lab to Sosua Site
SOSUA BAY, Dominican Republic, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Proton
Laboratories, Inc. (Pink Sheets
LBI) CEO, Armando Casciati, announced today
that the clean lab modular system has been released from customs and delivered
to the laboratory site across the street from the clinic in a standalone
facility. "We expect the lab to be installed and the remaining two pieces of
equipment to be delivered by the end of October," stated Mr. Casciati. Mr.
Casciati went on to say that "we are taking every precaution to construct this
laboratory to the standards needed to safeguard the process of stem cell
regeneration and with the supervision of Dr. Lee, we are confident that it will
be done properly. Once a patient's fatty tissue stem cells are removed and
analyzed, the lab will be the key factor in the regeneration of new stem cells
from clients and therefore must be processed in a very clean, secure environment
with detailed record keeping and culture identification. The lab will also be
the key in new research and development projects that may be presented.
About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:
RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings
the benefits of bioscience to patients who have been diagnosed with chronic
debilitating diseases, offering viable, efficient therapeutic options with
special Stem Cell Therapies utilizing the most effective cell regeneration
techniques. Therapies are tailored for each individual, based upon their
specific needs. Cells are obtained by the most modern technologic methods. The
transplant physicians and stem cell laboratory scientists, associated with RNL
Bio have been regarded as some of the best in the world. Stem cells derived from
Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from
a source other than your own) are used depending on the particular condition
that needs to be treated. Treatments will be delivered by an experienced team of
International and U.S. Board Certified Physicians who are guided by strict
protocols ensuring excellence in medical care.
About RNL Bio Company LTD:
RNL Bio is a premier biopharmaceutical company focused on development and
commercialization of adult stem cell therapeutics and dog cloning technology.
Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly
traded company on the Korea Exchange (Code 003190) and strives to become a
global leader across the biomedical industry.
OTCMB Alert: .007
Closed: .0102 +45.71%
Dear Subscribers,
Hopefully you got in on our featured stock PLBI today. It closed up +45.7% on
massive volume.
With a strong closing and unusually high volume, this could just be the
beginning of an even bigger rally. If you haven't already read the news, make
sure to do so (see below).
To better understand the significance of why investors are warming to PLBI and
wanting to become a part of it by investing, investors should carefully review
the website of its wholly owned subsidiary RegenoBody:
Stem Cell Therapy | Regenobody Stem Cells Treatment Clinic | Dominican Republic Stem Cells Clinic
PLBI is at the forefront of the most amazing medical breakthroughs to surface in
modern times.
From their website:
Adult Stem Cell Therapy is safe, highly effective and presents minimal risk. It
begins with a complete medical evaluation performed by the patient's personal
doctor, who will use the necessary documentation sent by us, to determine the
patient's overall health and eligibility for therapy.
Once qualified, Adult Stem Cells are extracted from the patient's own blood
and/or fat, via a standard draw procedure. Since it is the patient's own cells,
there is no possibility of the body rejecting its own stem cells. This makes the
procedure very safe and non-controversial. The few naturally occurring stem
cells are then cultivated into millions of RegenoCells.
The RegenoCell are then sent to their Clinics in Sosua and re-injected back
into the patient's via a IV or IM injection. There they stimulate tissue
re-growth and greater blood flow to the affected areas. Because RegenoCells are
extracted from the patient's own body they cannot be rejected by the patient's
body.
A full report is prepared by the treating physician. Follow-up exams will be
handled in the Dominican Republic at our RegenoBody Clinical Center, and all
medical information is provided to your personal physician.
Proton Laboratories Inc., (PLBI.PK), through Regenobody S.A. ("Regenobody"), a
Dominican Republic ("DR") company has been licensed by the DR government to
investigate, experiment, treat and develop autologus stem cells for regenerating
one's own cellular tissues. Regenobody has the exclusive rights in its territory
to the RNL BIO Company Ltd. of Korean systems and equipment for the banking,
manufacture and right to purchase stem cells from RNL-BIO for a period of 20
years. The license extends to all of the Caribean, Central and South America.
RNL-BIO Company Ltd.
? LATEST NEWS ?
Proton Laboratories, Inc./RegenoBody Announces Delivery of Lab to Sosua Site
SOSUA BAY, Dominican Republic, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Proton
Laboratories, Inc. (Pink Sheets
LBI) CEO, Armando Casciati, announced todaythat the clean lab modular system has been released from customs and delivered
to the laboratory site across the street from the clinic in a standalone
facility. "We expect the lab to be installed and the remaining two pieces of
equipment to be delivered by the end of October," stated Mr. Casciati. Mr.
Casciati went on to say that "we are taking every precaution to construct this
laboratory to the standards needed to safeguard the process of stem cell
regeneration and with the supervision of Dr. Lee, we are confident that it will
be done properly. Once a patient's fatty tissue stem cells are removed and
analyzed, the lab will be the key factor in the regeneration of new stem cells
from clients and therefore must be processed in a very clean, secure environment
with detailed record keeping and culture identification. The lab will also be
the key in new research and development projects that may be presented.
About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:
RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings
the benefits of bioscience to patients who have been diagnosed with chronic
debilitating diseases, offering viable, efficient therapeutic options with
special Stem Cell Therapies utilizing the most effective cell regeneration
techniques. Therapies are tailored for each individual, based upon their
specific needs. Cells are obtained by the most modern technologic methods. The
transplant physicians and stem cell laboratory scientists, associated with RNL
Bio have been regarded as some of the best in the world. Stem cells derived from
Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from
a source other than your own) are used depending on the particular condition
that needs to be treated. Treatments will be delivered by an experienced team of
International and U.S. Board Certified Physicians who are guided by strict
protocols ensuring excellence in medical care.
About RNL Bio Company LTD:
RNL Bio is a premier biopharmaceutical company focused on development and
commercialization of adult stem cell therapeutics and dog cloning technology.
Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly
traded company on the Korea Exchange (Code 003190) and strives to become a
global leader across the biomedical industry.
